mp.weixin.qq.com·· 9 hours agoPickScore82
FDA Approves Pfizer's Talazoparib Plus Enzalutamide for HRR-Mutated mHSPC, a First for PARP Inhibitors
In brief
On October 27 local time, the FDA approved Pfizer's talazoparib in combination with enzalutamide for adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Why it matters
TALAPRO-3 showed a 52% reduction in risk of radiographic progression or death and a difference in grade 3 or higher anemia; OS data remain immature.
Source: mp.weixin.qq.com · mp.weixin.qq.com